专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06770628B2 Hematopoietic stimulation 失效
标题翻译：造血刺激
公开(公告)号：US06770628B2
公开(公告)日：2004-08-03
申请号：US09878792
申请日：2001-06-11
申请人： Barbara P. Wallner , Barry Jones , Glenn T. Miller , Sharlene Adams
发明人： Barbara P. Wallner , Barry Jones , Glenn T. Miller , Sharlene Adams
IPC分类号： A61K3804
CPC分类号： A61K31/69 , A61K35/12 , A61K38/05 , A61K38/55 , A61K45/06
摘要： Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I: wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. A particularly preferred agent that is useful in practicing the invention is a ValBoroPro.
摘要翻译：提供了刺激造血作用的方法和产品，防止造血细胞水平降低并造成造血和成熟血细胞数量增加。方法和产品可以在体内和体外使用。所述方法包括施用式I的试剂：其中m为0至10的整数，包括端值; A和A1是L-氨基酸残基，使得每个重复括号中的A可以相同或不同的氨基酸残基; 与B结合的C处于L构型; A和N，A1和C之间以及A1和N之间的键是肽键; 并且每个X1和X2独立地是在生理pH下能够在水溶液中水解成羟基的羟基或基团。可用于实施本发明的特别优选的试剂是ValBoroPro。

2. 发明授权

US06300314B1 Hematopoietic stimulation 失效
标题翻译：造血刺激
公开(公告)号：US06300314B1
公开(公告)日：2001-10-09
申请号：US09304199
申请日：1999-05-03
申请人： Barbara P. Wallner , Barry Jones , Glenn T. Miller , Sharlene Adams
发明人： Barbara P. Wallner , Barry Jones , Glenn T. Miller , Sharlene Adams
IPC分类号： A61K3804
CPC分类号： A61K31/69 , A61K35/12 , A61K38/05 , A61K38/55 , A61K45/06
摘要： Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I: wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. A particularly preferred agent that is useful in practicing the invention is a ValBoroPro.
摘要翻译：提供了刺激造血作用的方法和产品，防止造血细胞水平降低并造成造血和成熟血细胞数量增加。方法和产品可以在体内和体外使用。所述方法包括施用式I的试剂：其中m为0至10的整数，包括端值; A和A1是L-氨基酸残基，使得每个重复括号中的A可以相同或不同的氨基酸残基; 与B结合的C处于L构型; A和N，A1和C之间以及A1和N之间的键是肽键; 并且每个X1和X2独立地是在生理pH下能够在水溶液中水解成羟基的羟基或基团。可用于实施本发明的特别优选的试剂是ValBoroPro。

3. 发明授权

US07067489B2 Hematopoietic stimulation 失效
标题翻译：造血刺激
公开(公告)号：US07067489B2
公开(公告)日：2006-06-27
申请号：US10879479
申请日：2004-06-28
申请人： Barbara P. Wallner , Barry Jones , Glenn T. Miller , Sharlene Adams
发明人： Barbara P. Wallner , Barry Jones , Glenn T. Miller , Sharlene Adams
IPC分类号： A61K31/40 , A61K38/04 , A61K38/05
CPC分类号： A61K31/69 , A61K35/12 , A61K38/05 , A61K38/55 , A61K45/06
摘要： Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. The products include kits comprising the agent of Formula I.
摘要翻译：提供了刺激造血作用的方法和产品，防止造血细胞水平降低并造成造血和成熟血细胞数量增加。方法和产品可以在体内和体外使用。所述方法包括施用式I的试剂，其中m为0至10的整数，包括端值; A和A 1是L-氨基酸残基，使得每个重复括号单元中的A可以相同或不同的氨基酸残基; 与B结合的C处于L构型; A和N之间的键，A 1和C以及A 1和N之间的键是肽键; 并且每个X 1和X 2独立地是在生理pH下能够在水溶液中水解成羟基的羟基或基团。产品包括包含式I的试剂的试剂盒。

4. 发明授权

US07259138B2 Anti-tumor agents 失效
公开(公告)号：US07259138B2
公开(公告)日：2007-08-21
申请号：US11131478
申请日：2005-05-17
申请人： Barbara P. Wallner , Glenn T. Miller
发明人： Barbara P. Wallner , Glenn T. Miller
IPC分类号： A61K31/40 , A61K38/02
CPC分类号： A61K31/69 , A61K38/00 , A61K45/06
摘要： A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.

5. 发明授权

US07282484B2 Anti-tumor agents 失效
标题翻译：抗肿瘤药
公开(公告)号：US07282484B2
公开(公告)日：2007-10-16
申请号：US11476524
申请日：2006-06-28
申请人： Barbara P. Wallner , Glenn T. Miller
发明人： Barbara P. Wallner , Glenn T. Miller
IPC分类号： A61K38/05
CPC分类号： A61K31/69 , A61K38/00 , A61K45/06
摘要： A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
摘要翻译：提供了治疗异常细胞增殖的受试者的方法。所述方法包括向需要这种治疗的受试者施用有效量的式I的药剂，以抑制细胞增殖，例如与肿瘤生长和转移相关的细胞增殖。还提供了通过给药式I的药剂来抑制异常增殖细胞团中的血管生成的方法。

6. 发明授权

US5728677A Methods of inhibiting T-cell dependent proliferation of peripheral blood lymphocytes using the CD2-binding domain of lymphocyte function associated antigen 3 失效
标题翻译：使用淋巴细胞功能相关抗原的CD2结合结构域抑制外周血淋巴细胞T细胞依赖性增殖的方法3
公开(公告)号：US5728677A
公开(公告)日：1998-03-17
申请号：US459512
申请日：1995-06-02
申请人： Barbara P. Wallner , Glenn T. Miller , Margaret D. Rosa
发明人： Barbara P. Wallner , Glenn T. Miller , Margaret D. Rosa
IPC分类号： A61K38/00 , A61K39/00 , A61P17/02 , A61P19/02 , A61P29/00 , A61P37/00 , A61P37/06 , C07K14/00 , C07K14/47 , C07K14/705 , C07K16/00 , C07K16/18 , C07K16/28 , C07K19/00 , C12N1/21 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12R1/91 , G01N33/53 , A61K38/17
CPC分类号： C07K14/70528 , C07K16/00 , A61K38/00 , C07K2317/73 , C07K2319/00 , C07K2319/02 , C07K2319/30 , C07K2319/75 , Y10S424/809 , Y10S435/81 , Y10S530/868
摘要： Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.
摘要翻译：公开了包含LFA-3的CD2结合结构域的多肽和蛋白质。还公开了编码那些多肽和蛋白质的表达的DNA序列，产生和使用那些多肽和蛋白质的方法，以及治疗和诊断组合物。还公开了不能结合CD2的缺失突变体及其使用方法。此外，公开了包含LFA-3的CD2结合结构域和一部分不同于LFA-3的蛋白质的融合蛋白，编码这些融合蛋白的DNA序列，产生这些融合蛋白的方法以及这些融合蛋白的用途的融合蛋白。

7. 发明申请

US20080221068A1 ANTI-TUMOR AGENTS 审中-公开
标题翻译：抗肿瘤药剂
公开(公告)号：US20080221068A1
公开(公告)日：2008-09-11
申请号：US11872371
申请日：2007-10-15
申请人： Barbara P. Wallner , Glenn T. Miller
发明人： Barbara P. Wallner , Glenn T. Miller
IPC分类号： A61K31/69 , A61P35/00
CPC分类号： A61K31/69 , A61K38/00 , A61K45/06
摘要： A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
摘要翻译：提供了治疗异常细胞增殖的受试者的方法。所述方法包括向需要这种治疗的受试者施用有效量的式I的药剂，以抑制细胞增殖，例如与肿瘤生长和转移相关的细胞增殖。还提供了通过给药式I的药剂来抑制异常增殖细胞团中的血管生成的方法。

8. 发明授权

US5928643A Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation 失效
标题翻译：使用淋巴细胞功能相关抗原3的CD2结合结构域启动T细胞活化的方法
公开(公告)号：US5928643A
公开(公告)日：1999-07-27
申请号：US460132
申请日：1995-06-02
申请人： Barbara P. Wallner , Glenn T. Miller , Margaret D. Rosa
发明人： Barbara P. Wallner , Glenn T. Miller , Margaret D. Rosa
IPC分类号： A61K38/00 , A61K38/17 , A61P37/04 , C07K14/705 , C12N15/12 , C12N15/62 , C12N15/70 , C12Q1/68 , A61K39/395 , A61K38/16
CPC分类号： C07K14/70528 , A61K38/1774 , C07K2319/00 , C07K2319/02 , C07K2319/30
摘要： Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.
摘要翻译：公开了包含LFA-3的CD2结合结构域的多肽和蛋白质。还公开了编码那些多肽和蛋白质的表达的DNA序列，产生和使用那些多肽和蛋白质的方法，以及治疗和诊断组合物。还公开了不能结合CD2的缺失突变体及其使用方法。此外，公开了包含LFA-3的CD2结合结构域和一部分不同于LFA-3的蛋白质的融合蛋白，编码这些融合蛋白的DNA序列，这些融合蛋白的制备方法和这些融合蛋白的用途。

9. 发明授权

US5914111A CD2-binding domain of lymphocyte function associated antigen-3 失效
标题翻译：淋巴细胞功能相关抗原-3的CD2结合结构域
公开(公告)号：US5914111A
公开(公告)日：1999-06-22
申请号：US459657
申请日：1995-06-02
申请人： Barbara P. Wallner , Glenn T. Miller , Margaret D. Rosa
发明人： Barbara P. Wallner , Glenn T. Miller , Margaret D. Rosa
IPC分类号： A61K38/00 , A61K39/00 , A61P17/02 , A61P19/02 , A61P29/00 , A61P37/00 , A61P37/06 , C07K14/00 , C07K14/47 , C07K14/705 , C07K16/00 , C07K16/18 , C07K16/28 , C07K19/00 , C12N1/21 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12R1/91 , G01N33/53 , A61K39/395 , A61K38/16 , C12N15/62
CPC分类号： C07K14/70528 , C07K16/00 , A61K38/00 , C07K2317/73 , C07K2319/00 , C07K2319/02 , C07K2319/30 , C07K2319/75 , Y10S424/809 , Y10S435/81 , Y10S530/868
摘要： Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.
摘要翻译：公开了包含LFA-3的CD2结合结构域的多肽和蛋白质。还公开了编码那些多肽和蛋白质的表达的DNA序列，产生和使用那些多肽和蛋白质的方法，以及治疗和诊断组合物。还公开了不能结合CD2的缺失突变体及其使用方法。此外，公开了包含LFA-3的CD2结合结构域和一部分不同于LFA-3的蛋白质的融合蛋白，编码这些融合蛋白的DNA序列，产生这些融合蛋白的方法以及这些融合蛋白的用途的融合蛋白。

10. 发明授权

US5547853A CD2-binding domain of lymphocyte function associated antigen 3 失效
标题翻译： CD2结合域淋巴细胞功能相关抗原3
公开(公告)号：US5547853A
公开(公告)日：1996-08-20
申请号：US940861
申请日：1992-10-21
申请人： Barbara P. Wallner , Glenn T. Miller , Margaret D. Rosa
发明人： Barbara P. Wallner , Glenn T. Miller , Margaret D. Rosa
IPC分类号： A61K38/00 , A61K39/00 , A61P17/02 , A61P19/02 , A61P29/00 , A61P37/00 , A61P37/06 , C07K14/00 , C07K14/47 , C07K14/705 , C07K16/00 , C07K16/18 , C07K16/28 , C07K19/00 , C12N1/21 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12R1/91 , G01N33/53 , C12N15/62
CPC分类号： C07K14/70528 , C07K16/00 , A61K38/00 , C07K2317/73 , C07K2319/00 , C07K2319/02 , C07K2319/30 , C07K2319/75 , Y10S424/809 , Y10S435/81 , Y10S530/868
摘要： Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.
摘要翻译： PCT No.PCT / US92 / 02050 Sec。 371日期：1992年10月21日 102（e）日期1992年10月21日PCT提交1992年3月12日PCT公布。第WO92 / 16622号公报日期：1992年10月1日公开了包含LFA-3的CD2结合结构域的多肽和蛋白质。还公开了编码那些多肽和蛋白质的表达的DNA序列，产生和使用那些多肽和蛋白质的方法，以及治疗和诊断组合物。还公开了不能结合CD2的缺失突变体及其使用方法。此外，公开了包含LFA-3的CD2结合结构域和一部分不同于LFA-3的蛋白质的融合蛋白，编码这些融合蛋白的DNA序列，这些融合蛋白的制备方法和这些融合蛋白的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式